Moreover, the DUET study (Komers et al., 2017) in patients with focal segmental glomerulosclerosis (FSGS) (Trachtman et al., 2018) demonstrated better renoprotection by sparsentan (dual RAS and ETA blocker) compared to irbesartan following 8 weeks of treatment: sparsentan being well tolerated and safe. The gene discussed is EDNRA; the disease is focal segmental glomerulosclerosis.